Aducanumab's Big Day Arrives, But How Much Will US FDA Panel Vote Matter?

 
• By Brenda Sandburg and Sue Sutter
Concept of memory loss and brain aging due to dementia and Alzheimer's disease as a medical icon with fall trees shaped as a human head losing leaves
Biogen's Alzheimer's disease drug aducanumab is facing an FDA advisory committee review • Source: Shutterstock

More from US FDA Performance Tracker

More from Regulatory Trackers